SMS Lifesciences Share Price Jumps 12% After USFDA EIR Receipt

SMS Lifesciences India Limited saw its share price soar 12% on July 16, 2025, after the company announced it had received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). 

USFDA EIR for Facility

SMS Lifesciences received the EIR from the USFDA for its API manufacturing facility at Kazipally, Telangana. The inspection concluded with a Voluntary Action Indicated (VAI) classification. This status confirms that although some issues were noted, no further regulatory action is required. The receipt of the EIR paves the way for SMS Lifesciences to continue exporting to the US and access other global markets.

Background and SEBI Compliance

The inspection update was first communicated by the company on May 9, 2025. The latest disclosure, submitted within 24 hours of EIR receipt, complies with SEBI’s circular dated December 31, 2024, ensuring timely transparency under Regulation 30 of the SEBI LODR Regulations, 2015.

SMS Lifesciences India Share Price Performance

On July 16, 2025, SMS Lifesciences India share price opened at ₹1,236.00 on NSE, above the previous close of ₹1,147.20. During the day, it surged to ₹1,376.60 and dipped to ₹1,164.30. The stock is trading at ₹1,276.00 as of 2:30 PM. The stock registered a significant gain of 12%.

Over the past week, it has moved up by 7.87%, over the past month, it has moved up by 13.13%, and over the past 3 months, it has moved up by 0.48%.

About SMS Lifesciences 

SMS Lifesciences is a global player in Pharmaceutical APIs/Intermediates manufacturing, having a strong research and manufacturing team supported by state-of-the-art facilities accredited by USFDA, Japan PMDA, WHO GMP, apart from other global regulatory authorities. The Company has been operating since 1990, with a Corporate office in Hyderabad, manufacturing facilities in Hyderabad and Vizag & research facilities in Hyderabad. 

SMS Lifesciences caters to leading generic and innovator customers globally. The company won accolades like “India Pharma Bulk Drug Company of the Year Award” fromthe  Government of India in 2020 and “Outstanding Export Performance Award 2018-19” in the “All round-Rising Star” Category from the Pharmaceuticals Export Promotion Council of India.

Read More: Hexaware Partners with Abluva to Strengthen AI Capabilities in Life Sciences Sector!

Conclusion

SMS Lifesciences’ share price rally underscores the importance of regulatory clearances in the pharmaceutical sector. The EIR with VAI status not only reinforces the company’s commitment to quality but also strengthens its position in key international markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.